Marc Lichtenfeld, who we’ve covered a number of times in this space, focuses largely on biotech investments — he’s teased a number of them for a variety of different newsletters that he has helmed or contributed to, but it looks like he’s now launching a new letter from the Oxford Club called FirstLine Investor Alert. [...]
Ah, a good old promise of biotech riches — I haven’t dug into one of these in ages, nothing beats the wild biotech stocks that can see their share price climb 200% (or fall 90%) on a single bit of news. This tease is from Marc Lichtenfeld, whose biotech stuff we’ve looked at several times [...]
Now this is a nice promise: “If This Stock Doesn’t Double Between Now and June 25, I’ll Write You an Apology – Along With a Check for $1,250″ Of course, one assumes that this only applies to the folks who pony up that same $1,250 for a subscription to the Access Research Group newsletter (and, [...]
This is an ad that probably many of you have already seen, from Marc Lichtenfeld for his Access Group newsletter. And yes, like so many ads do, they’re guaranteeing that you’ll double your money if you invest in this idea. Which gives me a chance for a quick little digression before we dig into the [...]
Today’s teaser ad is from Marc Lichtenfeld and his Access Group – they specialize in part on medical and biotech stocks, and the first two ads we’ve looked at them are in that area. The first one was for the “$4 Cancer Detection Device that could go to $196,” which you might remember turned out [...]
This one comes in from what looks to be a new newsletter service called “The Access Group” that will run you $2,750 a year. Phew. This is a service that they claim will enable individual investors to get access to the kind of research hedge fund companies used to pay these analysts $30,000 a year [...]
